RLMD - Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
- Relmada Therapeutics ( NASDAQ: RLMD ) said on Tuesday the U.S. Food and Drug Administration had granted Fast Track designation to its drug, REL-1017, as a monotherapy to treat major depressive disorder.
- ( RLMD ) rose 3.3% premarket.
- For a fast track drug, the company must show some advantage over current therapy, such as superior effectiveness, effect on serious outcomes or improved effect on serious outcomes, and avoiding serious side effects of an available therapy.
- A drug that receives Fast Track designation is eligible for Accelerated Approval and Priority Review.
For further details see:
Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression